510(k) · Cleared
ClearedAccess Rubella IgG
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Beckman Coulter, Inc. · LFX Enzyme Linked Immunoabsorbent Assay, Rubella
Cleared on Nov 17, 2025 as substantially equivalent to K954687 (Bio-Rad Laboratories, Inc., 1996) after a 263-day review. Its family tree reaches back 1 generation to 1996.
- Decided
- Nov 17, 2025
- Review
- 263 days
- Class
- Class II
- Product code
- LFX
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to K954687 (1996). No later device cites it as a predicate yet.
- Root · 1 generation backK954687 Access Rubella IggBio-Rad Laboratories, Inc. · 1996
- This deviceK250588 Access Rubella IgGBeckman Coulter, Inc. · 2025
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | K954687 | Access Rubella Igg | Bio-Rad Laboratories, Inc. | 1996 | — |
| 0 (this device) | K250588 | Access Rubella IgG | Beckman Coulter, Inc. | 2025 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LFX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LFX device
- #1 K243168 Alinity i Rubella IgGscore 9.8 · 2 generations · no Class I recall
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K954687 | Access Rubella IggSummary page 5…sification Name: Enzyme Linked Immunoabsorbent Assay, Rubella Classification Code: LFX Device Class: II Predicate Device Device Name: Access Rubella IgG 510(k) Numbers: K954687 Device Description The Access Rubella IgG assay is a paramagnetic-particle, chemiluminescent immunoassay for the qualitative an… | 1996 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has no recall.
- 1 other device also cites its predicate K954687.
How does its category compare?
All LFX devicesLFX Enzyme Linked Immunoabsorbent Assay, Rubella: FDA decisions, review times, recalls and adverse event reports over 20 years. 2025, this device’s year, is highlighted.
FDA decisions per year · LFX
2in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · LFX
354in 2008
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · LFX
1in 2021
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · LFX
12in 2025
MAUDE reports naming product code LFX, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 1 | — | 2 | 5 |
| 2008 | 3 | 354 | 2 | 367 |
| 2009 | 0 | — | 3 | 19 |
| 2010 | 2 | — | 2 | 18 |
| 2011 | 1 | — | 1 | 89 |
| 2012 | 1 | — | 0 | 37 |
| 2013 | 0 | — | 0 | 15 |
| 2014 | 0 | — | 0 | 13 |
| 2015 | 0 | — | 0 | 15 |
| 2016 | 0 | — | 2 | 47 |
| 2017 | 0 | — | 0 | 10 |
| 2018 | 0 | — | 0 | 24 |
| 2019 | 0 | — | 0 | 16 |
| 2020 | 0 | — | 0 | 21 |
| 2021 | 0 | — | 1 | 13 |
| 2022 | 0 | — | 0 | 13 |
| 2023 | 0 | — | 0 | 7 |
| 2024 | 0 | — | 0 | 13 |
| 2025 | 2 | — | 0 | 12 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The Access Rubella IgG assay is a paramagnetic-particle, chemiluminescent immunoassay for the qualitative and
quantitative determination of IgG antibodies to the rubella virus in human serum using the Access Immunoassay Systems.
The Access Rubella IgG assay aids in the diagnosis of rubella infection and the determination of immunity.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K250588 · printed Nov 6, 2026
Cite this page
510(k) Report. “K250588: Access Rubella IgG.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K250588
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026